Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

6.8K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
6.8K
Tumor Immunotherapy01:27

Tumor Immunotherapy

1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
Cancers Originate from Somatic Mutations in a Single Cell02:21

Cancers Originate from Somatic Mutations in a Single Cell

14.4K
Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
14.4K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

9.3K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
9.3K
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

5.8K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
5.8K
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

6.3K
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
6.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Editorial Expression of Concern: Recognition of the nonclassical MHC class I molecule H2-M3 by the receptor Ly49A regulates the licensing and activation of NK cells.

Nature immunology·2026
Same author

Correction: Contribution of IL-17-producing γδ T cells to the efficacy of anticancer chemotherapy.

The Journal of experimental medicine·2026
Same author

Author Correction: IFN-γ is required for cytotoxic T cell-dependent cancer genome immunoediting.

Nature communications·2024
Same author

TIGIT predominantly regulates the immune response via regulatory T cells.

The Journal of clinical investigation·2024
Same author

NK cell heparanase controls tumor invasion and immune surveillance.

The Journal of clinical investigation·2024
Same author

Correction: DX5/CD49b-Positive T Cells Are Not Synonymous with CD1d-Dependent NKT Cells.

Journal of immunology (Baltimore, Md. : 1950)·2024

Related Experiment Video

Updated: Dec 25, 2025

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

1.3K

Innate Cancer Immunoediting.

Tobias Bald1, Mark J Smyth2

  • 1Oncology and Cellular Immunology Laboratory, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.

The Journal of Investigative Dermatology
|March 24, 2020
PubMed
Summary

Cancer immunoediting involves immune cells eliminating early cancer. This study reveals innate immune cells play a crucial role in the immunoediting of early transformed epithelial cells, challenging previous adaptive immunity focus.

More Related Videos

Monitoring the Cancer-Immunity Cycle and Exploring Tumor Microenvironment Dynamics
12:19

Monitoring the Cancer-Immunity Cycle and Exploring Tumor Microenvironment Dynamics

Published on: June 7, 2024

1.8K
Evaluation of Tumor-infiltrating Leukocyte Subsets in a Subcutaneous Tumor Model
07:49

Evaluation of Tumor-infiltrating Leukocyte Subsets in a Subcutaneous Tumor Model

Published on: April 13, 2015

20.7K

Related Experiment Videos

Last Updated: Dec 25, 2025

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

1.3K
Monitoring the Cancer-Immunity Cycle and Exploring Tumor Microenvironment Dynamics
12:19

Monitoring the Cancer-Immunity Cycle and Exploring Tumor Microenvironment Dynamics

Published on: June 7, 2024

1.8K
Evaluation of Tumor-infiltrating Leukocyte Subsets in a Subcutaneous Tumor Model
07:49

Evaluation of Tumor-infiltrating Leukocyte Subsets in a Subcutaneous Tumor Model

Published on: April 13, 2015

20.7K

Area of Science:

  • Immunology
  • Oncology
  • Cell Biology

Background:

  • Immune cells are crucial for detecting and destroying cancer cells.
  • Cancer immunoediting is a process where cancer cells evolve to evade the immune system.
  • Adaptive immunity's role in immunoediting is well-established, but the innate immune system's contribution is less understood.

Purpose of the Study:

  • To investigate the role of innate immune cells in the immunoediting of early transformed epithelial cells.
  • To provide novel insights into the mechanisms of cancer immune escape.
  • To highlight the contribution of innate immunity in the context of cancer immunoediting.

Main Methods:

  • The study likely involved in vitro or in vivo models of early transformed epithelial cells.
  • Analysis of immune cell interactions with these transformed cells.
  • Assessment of immune cell-mediated elimination or selection of cancer variants.

Main Results:

  • Innate immune cells significantly contribute to the immunoediting of early transformed epithelial cells.
  • The findings challenge the predominant focus on adaptive immunity in cancer immunoediting.
  • Early genomic and phenotypic changes in cancer cells are critical for immune escape.

Conclusions:

  • Innate immune cells are key players in the early stages of cancer immunoediting.
  • Understanding innate immune cell functions can reveal new therapeutic targets for cancer.
  • The interplay between cancer evolution and innate immunity is vital for controlling tumor development.